Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators

International Journal of Antimicrobial Agents

Volumn 31, Issue 1, 2008, Pages 12-20

  Giamarellos Bourboulis, Evangelos J ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bronchial asthma; Cystic fibrosis; Diffuse panbronchiolitis; Inflammation; Macrolides; Sepsis

Indexed keywords

AMIKACIN; AMOXICILLIN; AZITHROMYCIN; CLARITHROMYCIN; CYTOKINE; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTONE; LEVOFLOXACIN; MACROLIDE; MIDECAMYCIN; PLACEBO; SODIUM CHLORIDE; TELITHROMYCIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BACTERIAL COLONIZATION; BIOFILM; BRONCHIECTASIS; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; EPITHELIUM; EPITHELIUM CELL; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE SEPSIS; HUMAN; MONOCYTE; MUCUS SECRETION; NAUSEA; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; QUORUM SENSING; RASH; SHORT SURVEY; SIDE EFFECT; URTICARIA; VENTILATOR ASSOCIATED PNEUMONIA; WHEEZING;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMMUNOLOGIC FACTORS; MACROLIDES; RESPIRATORY TRACT DISEASES;

EID: 36849073243     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.08.001     Document Type: Short Survey

References (75)

1. Rubin B.K., and Henke M.O. Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest 125 Suppl. 2 (2004) 70-78
2. Pasquale T.R., and Tan J.S. Non-antimicrobial effects of antibacterial agents. Clin Infect Dis 40 (2005) 127-135
3. Martίnez J.A., Horcajada J.P., Almela M., et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 36 (2003) 389-395
4. Vázquez E.G., Mensa J., Martίnez J.A., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 24 (2005) 190-195
5. Costerton J.W., Stewart P.S., and Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 284 (1999) 1318-1322
6. Vlastarakos P.V., Nikolopoulos T.P., Maragoudakis P., Tzagaroulakis A., and Ferekidis E. Biofilms in ear, nose, and throat infections: how important are they?. Laryngoscope 117 (2007) 668-673
7. Donabedian H. Quorum sensing and its relevance to infectious diseases. J Infect 46 (2003) 207-214
8. Hentzer M., and Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Invest 112 (2003) 1300-1307
9. Wozniak D.J., and Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 125 Suppl. 2 (2004) 62-69
10. Gillis R.J., and Iglewski B.H. Azithromycin retards Pseudomonas aeruginosa biofilm formation. J Clin Microbiol 42 (2004) 5842-5845
11. Nalca Y., Jänsch L., Bredenbruch F., Geffers R., Buer J., and Häussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PA01: a global approach. Antimicrob Agents Chemother 50 (2006) 1680-1688
12. Tateda K., Comte R., Pechère J.C., Köhler T., Yamaguchi K., and Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 (2001) 1930-1933
13. Yanagihara K., Tomono K., Imamura Y., et al. Effect of clarithromycin on chronic respiratory infection caused by Pseudomonas aeruginosa with biofilm formation in an experimental murine model. J Antimicrob Chemother 49 (2002) 867-870
14. Yanagihara K., Tomono K., Sawai T., et al. Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother 46 (2000) 69-72
15. Liaudet L., Szabo C., Evgenov O.V., et al. Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock 19 (2003) 131-137
16. Shinkai M., López-Boado Y.S., and Rubin B.K. Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. J Antimicrob Chemother 59 (2007) 1096-1101
17. Shinkai M., Foster G.H., and Rubin B.K. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 290 (2006) L75-L85
18. Shinkai M., Tamaoki J., Kobayashi H., et al. Clarithromycin delays progression of bronchial epithelial cells from G1 phase to S phase and delays cell growth via extracellular signal-regulated protein kinase suppression. Antimicrob Agents Chemother 50 (2006) 1738-1744
19. Asgrimsson V., Gudjonsson T., Gudmundsson G.H., and Baldursson O. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob Agents Chemother 50 (2006) 1805-1812
20. Demarini G., Esposti D., Marthyn P., Lapidari A., Fraschini F., and Scaglione F. Effect of multiple doses of clarithromycin and amoxicillin on IL-6, IFNγ and IL-10 plasma levels in patients with community acquired pneumonia. J Chemother 16 (2004) 82-85
21. Reato G., Cuffini A.M., and Tullio V. Immunomodulating effect of antimicrobial agents on cytokine production by human polymorphonuclear neutrophils. Int J Antimicrob Agents 23 (2004) 150-154
22. Kikuchi T., Hagiwara K., Honda Y., et al. Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-κB transcription factors. J Antimicrob Chemother 49 (2002) 745-755
23. Sato Y., Kaneko K., and Inoue M. Macrolide antibiotics promote the LPS-induced upregulation of prostaglandin E receptor EP2 and thus attenuate macrolide suppression of IL-6 production. Prostaglandins Leukot Essent Fatty Acids 76 (2007) 181-188
24. Borszcz P.D., Befus D., Moqbel R., et al. Effects of clarithromycin on inflammatory cell mediator release and survival. Chemotherapy 51 (2005) 206-210
25. Yamaryo T., Oishi K., Yoshimine H., Tsuchihashi Y., Matsushima K., and Nagatake T. Fourteen-member macrolides promote the phosphatidylserine receptor-dependent phagocytosis of apoptotic neutrophils by alveolar macrophages. Antimicrob Agents Chemother 47 (2003) 48-53
26. Hodge S., Hodge G., Brozyna S., Jersmann H., Holmes M., and Reynolds P.N. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 28 (2006) 486-495
27. Sugiyama K., Shirai R., Mukae H., et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol 147 (2007) 540-546
28. Williams A.C., Galley H.F., Watt A.M., and Webster N.R. Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother 56 (2005) 502-506
29. Darkes M.J., and Perry C.M. Clarithromycin extended-release tablet: a review of its use in the management of respiratory tract infections. Am J Respir Med 2 (2003) 175-201
30. Williams K.N., and Bishai W.R. Clarithromycin extended-release in community-acquired respiratory tract infections. Expert Opin Pharmacother 6 (2005) 2867-2876
31. Wierzbowski A.K., Hoban D.J., Hisanaga T., DeCorby M., and Zhanel G.G. The use of macrolides in treatment of upper respiratory tract infections. Curr Allergy Asthma Rep 6 (2006) 171-181
32. Danesi R., Lupetti A., and Barbara C. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. J Antimicrob Chemother 51 (2003) 939-945
33. Hatipoglu U., and Rubinstein I. Low-dose, long-term macrolide therapy in asthma: an overview. Clin Mol Allergy 2 (2004) 4
34. Ferrara G., Losi M., Franco F., Corbetta L., Fabbri L.M., and Richeldi L. Macrolides in the treatment of asthma and cystic fibrosis. Respir Med 99 (2005) 1-10
35. Garey K.W., Rubinstein I., Gotfried M.H., Khan I.J., Varma S., and Danziger L.H. Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 118 (2000) 1826-1827
36. Gotfried M.H. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125 Suppl. 2 (2004) 52-61
37. Kraft M., Cassell G.H., Pak J., et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 121 (2002) 1782-1788
38. Kostadima E., Tsiodras S., Alexopoulos E.I., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 23 (2004) 714-717
39. Piacentini G.L., Peroni D.G., Bodini A., et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: a preliminary report. Allergy Asthma Proc 28 (2007) 194-198
40. Johnston S.L., Blasi F., Black P.N., et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 354 (2006) 1589-1600
41. Hoiby N. New antimicrobials in the management of cystic fibrosis. J Antimicrob Chemother 49 (2002) 235-238
42. Southern K.W., and Barker P.M. Azithromycin in cystic fibrosis. Eur Respir J 24 (2004) 834-838
43. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
44. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomized, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
45. Saiman L., Marshall B.C., Mayer-Hamblett N., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
46. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., and Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61 (2006) 895-902
47. Carfartan G., Gerardin P., Turck D., and Husson M.O. Effect of subinhibitory concentrations of azithromycin on adherence of Pseudomonas aeruginosa to bronchial mucins collected from cystic fibrosis patients. J Antimicrob Chemother 53 (2004) 686-688
48. Nguyen D., Emond M.J., Mayer-Hamblett N., Saiman L., Marshall B.C., and Burns J.L. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 42 (2007) 533-541
49. Equi A.C., Davies J.C., Painter H., et al. Exploring the mechanisms of macrolides in cystic fibrosis. Respir Med 100 (2006) 687-697
50. Barker P.M., Gillie D.J., Schechter M.S., and Rubin B.K. Effect of macrolides on in vivo iron transport across cystic fibrosis nasal epithelium. Am J Respir Crit Care Med 171 (2005) 868-871
51. Pukhalsky A.L., Shmarina G.V., Kapranov N.I., Kokarovtseva S.N., Pukhalskaya D., and Kashirskaja N.J. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm 13 (2004) 111-117
52. Cigana C., Nicolis E., Pasetto M., Assael B.M., and Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 350 (2006) 977-982
53. Cigana C., Assael B.M., and Melotti P. Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells. Antimicrob Agents Chemother 51 (2007) 975-981
54. Amsden G.W. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 55 (2005) 10-21
55. Schultz M.J. Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 54 (2005) 21-28
56. Kadota J., Mukae H., Ishii H., et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 97 (2003) 844-850
57. Kaneko Y., Yanagihara K., Seki M., et al. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 285 (2003) L847-L853
58. Verleden G.M., Vanaudenaerde B.M., Dupont L.J., and van Raemdonck D.E. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 174 (2006) 566-570
59. Stover D.E., and Mangino D. Macrolides. A treatment alternative for bronchiolitis obliterans organizing pneumonia?. Chest 128 (2004) 3611-3617
60. Tamaoki J., Kadota J., and Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 117 (2004) 5S-11S
61. Shimizu T., Shimizu S., Hattori R., Gabazza E.C., and Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 168 (2003) 581-587
62. Parnham M.J., Ćulić O., Eracović V., et al. Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. Eur J Pharmacol 517 (2005) 132-143
63. Basyigit I., Yidiz F., Ozkara S.K., Yildirim E., Boyaci H., and Ilgazli A. The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother 38 (2004) 1400-1405
64. Yalçin E., Kiper N., O{combining double acute accent}zçelik U., et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 31 (2006) 49-55
65. Giamarellos-Bourboulis E.J., Adamis T., Laoutaris G., et al. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 48 (2004) 93-99
66. Giamarellos-Bourboulis E.J., Antonopoulou A., Raftogiannis M., et al. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa. BMC Infect Dis 6 (2006) 31
67. Giamarellos-Bourboulis E.J., Baziaka F., Antonopoulou A., et al. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis by Escherichia coli. Int J Antimicrob Agents 25 (2005) 168-172
68. Giamarellos-Bourboulis E.J., Adamis T., Sabracos L., et al. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli. Scand J Infect Dis 37 (2005) 48-54
69. Giamarellos-Bourboulis E.J., Tziortzioti V., Koutoukas P., et al. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae. J Antimicrob Chemother 57 (2006) 937-944
70. Antonopoulou A., Raftogiannis M., Giamarellos-Bourboulis E.J., et al. Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant Pseudomonas aeruginosa. Clin Exp Immunol 149 (2007) 103-108
71. Tkalčević V.I., Bošnjak B., Hračić B., et al. Anti-inflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur J Pharmacol 539 (2006) 131-138
72. Tahan F., Ozcan A., and Koc N. Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomized, placebo-controlled trial. Eur Respir J 29 (2007) 91-97
73. Malhotra-Kumar S., Lammens C., Coenen S., van Herck K., and Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: a randomised, double-blind, placebo-controlled study. Lancet 369 (2007) 482-490
74. Tramper-Stranders G.A., Wolfs T.F., Fleer A., Kimpen J.L., and van der Ent C.K. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 26 (2007) 8-12
75. Phaff S.J., Tiddens H.A.W.M., Verbrugh H.A., and Ott A. Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57 (2006) 741-746